Resultados de la búsqueda 31-40 of 1413 for ���������������������������op������r���:za33���

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered once a day (QD) as a single agent and in combination with dexamethasone. A Study ...

  3. Neurología - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to evaluate the safety, pharmacokinetics and biodistribution of an imaging agent, 18F-OP-801 (18F Hydroxyl Dendrimer), ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

  5. Hematología - Ensayos clínicos - Mayo Clinic

    Patients in the GDC-0199+R arm will continue GDC-0199 treatment until disease progression or 2 years since treatment start, whichever comes first. Anticipated ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

  7. Hematología - Ensayos clínicos - Mayo Clinic

    ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...